MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment.
Eur Rev Med Pharmacol Sci
; 24(8): 4537-4538, 2020 04.
Статья
в английский
| MEDLINE | ID: covidwho-199034
ABSTRACT
At present, SARS-Cov-2 is spread all over the world, becoming a serious threat to people's health. SARS-Cov-2 has a strong infection, and the mortality rate of severe patients after infection is high, but there is no effective treatment. Mesenchymal stem cells (MSCs) have anti-inflammatory and immunomodulatory functions, which can reduce the occurrence of cytokine storm syndrome and acute respiratory distress syndrome. At the same time, MSCs can reduce the level of pulmonary fibrosis and enhance tissue injury repair. In this short report, combined with the progress of preclinical and clinical research, we comment the efficacy of MSCs in the treatment of COVID-19.
Полный текст:
Имеется в наличии
Коллекция:
Международные базы данных
база данных:
MEDLINE
Основная тема:
Pneumonia, Viral
/
Coronavirus Infections
/
Mesenchymal Stem Cell Transplantation
Тип исследования:
Прогностическое исследование
Пределы темы:
Животные
/
Люди
Язык:
английский
Журнал:
Eur Rev Med Pharmacol Sci
Тематика журнала:
Фармакология
/
Токсикология
Год:
2020
Тип:
Статья
Аффилированная страна:
Eurrev_202004_21037
Документы, близкие по теме
MEDLINE
...
LILACS
LIS